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Abstract
Sorafenib has been considered the standard of care 
for patients with advanced unresectable hepatocellular 
carcinoma (HCC) since 2007 and numerous studies 
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have investigated the role of markers involved in the 
angiogenesis process at both the expression and 
genetic level and clinical aspect. What results have 
ten years of research produced? Several clinical and 
biological markers are associated with prognosis. The 
most interesting clinical parameters are adverse events, 
Barcelona Clinic Liver Cancer stage, and macroscopic 
vascular invasion, while several single nucleotide 
polymorphisms and plasma angiopoietin-2 levels 
represent the most promising biological biomarkers. 
A recent pooled analysis of two phase III randomized 
trials showed that the neutrophil-to-lymphocyte ratio, 
etiology and extra-hepatic spread are predictive factors 
of response to sorafenib, but did not identify any 
predictive biological markers. After 10 years of research 
into sorafenib there are still no validated prognostic or 
predictive factors of response to the drug in HCC. The 
aim of the present review was to summarize 10 years 
of research into sorafenib, looking in particular at the 
potential of associated clinical and biological markers to 
predict its efficacy in patients with advanced HCC.
Key words: Biomarker; Angiopoietin; Neutrophil-to-
lymphocyte ratio; Polymorphisms; Sorafenib; MicroRNA; 
Adverse events; Hepatocellular carcinoma; Vascular 
endothelial growth factor
© The Author(s) 2018. Published by Baishideng Publishing 
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Core tip: Sorafenib has been considered the standard 
of care for patients with advanced unresectable 
hepatocellular carcinoma, but after 10 years of research 
into sorafenib response or resistance, there are still no 
validated prognostic or predictive factors of response. 
Marisi G, Cucchetti A, Ulivi P, Canale M, Cabibbo G, Solaini 
L, Foschi FG, De Matteis S, Ercolani G, Valgiusti M, Frassineti 
GL, Scartozzi M, Casadei Gardini A. Ten years of sorafenib 
in hepatocellular carcinoma: Are there any predictive and/or 
prognostic markers? World J Gastroenterol 2018; 24(36): 
4152-4163  Available from: URL: http://www.wjgnet.
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INTRODUCTION
Sorafenib, an oral multikinase inhibitor, has been 
considered the standard of care for patients with 
advanced unresectable hepatocellular carcinoma (HCC) 
since 2007[1]. It works by inhibiting the activity of 
several tyrosine kinases involved in tumor angiogenesis 
and progression, including vascular endothelial 
growth factor receptor (VEGFR-2/3), platelet-derived 
growth factor receptor (PDGF-R), Flt3 and c-Kit, and 
also targets Raf kinases involved in the MAPK/ERK 
pathway[2] (Figure 1). The molecular mechanisms by 
which sorafenib exerts its activity have still not been 
fully elucidated, and both Raf/MEK/ERK-dependent and 
-independent mechanisms have been observed[3].
Sorafenib is expensive and associated with adverse 
events (AEs). Furthermore, a proportion of treated 
patients show no response to the drug. It would thus be 
useful to have predictive markers capable of identifying 
those who are more likely to benefit from therapy. The 
availability of more accurate predictive or prognostic 
factors would also help to spare potentially resistant 
patients from unnecessary toxicity. 
Ten years have passed since sorafenib was first 
commercialized and about 2800 studies have been 
published on the kinase inhibitor. But how many 
associated prognostic and/or predictive markers have 
been identified? Numerous studies have focused on the 
role of markers involved in the angiogenesis process 
at both the expression and genetic levels. The largest 
biomarker study conducted to date is the SHARP trial[4], 
which included an adequate number of participants and 
a placebo-controlled group. Smaller single-arm studies 
exploring predictive or prognostic markers for sorafenib 
have also been conducted, but the results of these have 
yet to be validated.
The aim of the present review was to summarize 
10 years of research into sorafenib, looking in particular 
at the potential of associated clinical and biological 
markers to predict its efficacy in patients with advanced 
HCC (Tables 1 and 2).
CLINICAL PARAMETERS
Alpha-fetoprotein
Alpha-fetoprotein (AFP) is secreted by about 50% of all 
HCCs and is the main serological marker used for the 
diagnosis of the tumor[5]. The SHARP trial[4] showed that 
high baseline AFP plasma levels (> 200 ng/mL) had 
a negative impact on overall survival (OS), a finding 
recently confirmed in a pooled analysis of the SHARP 
trial and the Asia Pacific trial by Bruix et al[6]. High 
baseline serum AFP levels (≥ 400 ng/mL) also appear 
to be associated with shorter time-to-progression 
(TTP). Notably, in an analysis of six prospective phase 
II trials evaluating systemic therapies for patients with 
advanced HCC, no association was observed between 
baseline AFP levels and prognosis[7]. 
Several studies[8-10] have highlighted a consistent 
correlation between an early decrease of > 20% in 
AFP levels following sorafenib and objective response 
and better outcome in advanced HCC patients. Shao 
et al[8] evaluated for the first time this aspect and they 
observed that patients with early AFP response had an 
improved progression-free survival (PFS) (7.5 mo vs 
1.9 mo) and OS (15.3 mo vs 4.1 mo). This data was 
confirmed by Personeni et al[10] a few years later. They 
reported that early responders had a significantly better 
median OS and TTP than non-responders (13.8 mo vs 
8.2 mo, P = 0.022 and 7.9 mo vs 2.4 mo, P = 0.004; 
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respectively). Conversely, Nakazawa et al[11] did not 
observe such an association.
Adverse events
The main AEs of Sorafenib are hand-foot skin reaction 
(HFSR), hypertension and diarrhea. Several papers 
have highlighted a consistent correlation between AEs 
and survival in patients treated with Sorafenib.
Vincenzi et al[12] evaluated for the first time the 
correlation between HSFR and outcome. They showed, 
in a small series of patients treated with sorafenib, that 
patients with HSFR had a significantly higher disease 
control rate with respect to patients without HSFR. 
This data was confirmed in a prospective study of 
147 patients by Reig et al[13]. They reported different 
OS when patients were subdivided according to the 
presence or not of skin toxicity during the first 60 d of 
treatment (18.2 mo vs 10.1 mo, respectively)[13] . A 
4154 September 28, 2018|Volume 24|Issue 36|WJG|www.wjgnet.com
Table 1  Predictive and/or prognostic value of clinical markers in hepatocellular carcinoma patients
Clinical markers Predictive value Prognostic value Ref.
Alpha-fetoprotein No Yes [6]
Adverse events
Hand-foot skin reaction No Yes [13]
Hypertension No Uncertain [16,19,20]
Diarrhea No Yes [21]
Child-Pugh A vs B No Yes [27-29]
Macroscopic vascular invasion No Yes [6]
BCLC B vs C No Yes [6,29,32]
Starting dose and dose reduction No Yes [29,32]
Etiology HCV vs HBV Yes Yes [6]
Chronic treatment with metformin No Yes [35,36]
Neutrophil-to-lymphocyte ratio Yes Yes [6,41,44]
Extra hepatic spread Yes Yes [6]
HCC: Hepatocellular carcinoma; BCLC: Barcelona Clinic Liver Cancer; HCV: Hepatitis C virus; HBV: Hepatitis B virus.
Ang1 Ang2
PDGF-b VEGF SCF Flt3 ligand
Flt3c-KITVEGFRPDGFRTie2
Ras
Raf-1P
P
P ERK
MEK
Angiogenesis
Proliferation/migration
Survival
Metastasis
Nucleus
Endothelial cell survival
NO
eNOS
Akt/PkB
PI3K
Sorafenib inhibition
Endothelial cell
Figure 1  Sorafenib pathaway and the main molecular factors. Ang: Angiopoietin; Tie2: Tyrosine-protein kinase receptor; PDGFR: Platelet-derived growth factor 
receptors; VEGFR: Vascular endothelial growth factor receptor; SCF: Stem cell factor; PI3K: PhosphatidylInositol 3-Kinase; Akt/PKB: Protein-chinasi B; eNOS: 
Endothelial nitric oxide synthase; NO: Nitric oxide; P: Phospho-; MEK: Mitogen-activated protein kinase kinase; ERK: Extracellular signal–regulated kinase.
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0, 1 and 2, respectively; P = 0.014). These data were 
subsequently confirmed in the validation cohort[24]. 
A recent meta-analysis by Abdel-Rahman et al[25] 
revealed an association between specific side-effects 
(hypertension, HFSR and diarrhea) and patient outcome 
(HR = 0.38; 95%CI: 0.30-0.48; P < 0.00001).
Stage, liver functionality and etiology 
Child-Pugh A vs Child-Pugh B: In the SHARP trial[4] 
and the Asia Pacific trial[26], more than 95% of patients 
were classified as having Child-Pugh A cirrhosis, thus 
preventing the investigation of the potential benefits of 
sorafenib in Child-Pugh B patients. 
Hollebecque et al[27] reported for the first time the 
results from a prospective study on sorafenib efficacy 
in 120 advanced HCC patients, 20 of whom Child-Pugh 
B cirrhosis. OS was 11.1 mo, with a significantly longer 
median survival in Child-Pugh A patients than Child-
Pugh B patients (13 mo vs 4.5 mo, P = 0.0008). A few 
years later, Pressiani et al[28] studied clinical outcome 
in a population of 300 consecutive patients; PFS in the 
Child-Pugh A group was 4.3 mo vs 2.1 mo in the Child-
Pugh B arm (HR = 3.23; 95%CI: 2.38-4.39; P < 0.001), 
TTP was 4.2 mo vs 3.8 mo and OS was 10.0 mo vs 3.8 
mo, respectively (P < 0.001).
recently meta-analysis confirmed that HSFR was a good 
indicator of outcome for OS and TTP in HCC patients 
receiving sorafenib[14]
Hypertension (HTN) is frequently associated with 
the use of angiogenesis inhibitors[15]. Casadei Gardini 
et al[16] showed that early HTN (15 d after the start 
of treatment) rather than later onset HTN vs patients 
without HTN was associated with better PFS (6.0 mo 
vs 2.5 mo; P < 0.001) and OS (14.6 mo vs 3.9 mo; 
P = 0.003). This finding has been confirmed in some 
studies[17,18] but not in others[19,20]. 
Bettinger et al[21] reported for the first time that 
diarrhea was an independent positive prognostic factor 
(HR = 0.41; P = 0.001) in 112 patients with advanced 
HCC, a finding also confirmed by Koschny et al[22]. 
Finally, other authors showed that the number of 
AEs was associated with predict survival in patients 
treated with sorafenib. In particular, Di Costanzo et al[23] 
evaluated the potential of pretreatment clinical variables 
to predict survival. Three groups of patients were taken 
into account: patients without AEs (group 0), patients 
with one AE (group 1) and patients with two to three 
AEs (group 2). The study reported a strong correlation 
between this classification and disease progression at 
3 mo (41.9%, 25.9% and 12.7% of patients in groups 
Table 2  Predictive and/or prognostic value of biological markers in hepatocellular carcinoma patients
Biological markers Predictive value Prognostic value Ref.
Serum and plasma proteins
   VEGF-A No Uncertain [4,57]
   Ang-2 No Yes [4]
   IGF-1 No No [55]
Single nucleotide polymorphisms 
   VEGF-A rs2010963 No Yes [65]
   VEGF-C rs4604006 No Yes [65]
   eNOS (eNOS-786/eNOS VNTR) No Yes [66]
   Ang-2 rs55633437 No Yes [67]
   HIF-1 alpha rs12434438 No Yes [68]
Amplifications
   VEGF No Uncertain [70]
   FGF3/FGF4 No Uncertain [71]
miRNAs
   miR-425-3p No Yes [74]
   miR-224 No Yes [75]
   miR-181a-5p No Yes [77]
   miR-339-5p No Yes [77]
   miR-423-5p No Yes [78]
   miR-10b-3p No Yes [79]
   miR-221 No Uncertain [76]
Tissue biomarker expression
   Phospho-ERK Uncertain Uncertain [81,82]
   PDGFR-b No Yes [84]
   c-Met No No [84]
   VEGFR No No [84]
   p-c-Jun No Yes [85]
Ang-2: Angiopoietin-2; IGF-1: Insulin-like growth factor-1; VEGF-A: Vascular endothelial growth factor A; HIF-1: Hypoxia-inducible factor 1; FGF: 
Fibroblast growth factor; miRNAs: MicroRNAs; eNOS: Endothelial nitric oxide synthase; PDGFR: Platelet-derived growth factor receptors; VEGFR: 
Vascular endothelial growth factor receptor; ERK: Extracellular signal–regulated kinase.
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The most important work on the use of sorafenib in 
Child-Pugh subgroups was the GIDEON study published 
in 2016[29]. This study observed that median OS was 
significantly longer in patients with Child-Pugh A (13.6 
mo) than in those with Child Pugh B (5.2 mo) or Child-
Pugh C (2.6 mo).
Macroscopic vascular invasion: It is widely 
acknowledged that the presence of macroscopic 
vascular invasion leads to a poorer prognosis[26,30]. The 
meta-analysis by Peng et al[31] confirmed its prognostic 
value and the pooled analysis by Bruix et al[6] affirmed 
the importance of macroscopic vascular invasion as a 
predictor of survival but not of response to treatment. 
BCLC stage: In the SHARP trial, patients with 
Barcelona Clinic Liver Cancer (BCLC) B had a median 
OS of 14.5 mo compared to 9.7 mo for those with BCLC 
C[4]. Later, SOFIA[32] and GIDEON study[29] confirmed 
this data. In the SOFIA trial[32] the OS was 8.4 mo in 
BCLC C vs 20.6 mo in BCLC B patients (P < 0.0001), 
but the time to radiologic progression did not differ 
significantly between the 2 groups. In the GIDEON 
study[29], median OS according to BCLC by Child-Pugh 
cross-classification followed a similar trend, i.e. patients 
with Child-Pugh A and BCLC stage B showed longer OS 
than those with Child-Pugh B and BCLC B (19.5 mo vs 
10.0 mo); and patients with Child-Pugh A and BCLC 
stage C had longer OS than those with Child-Pugh B 
and BCLC stage C (11.2 mo vs 3.8 mo). 
Recently, Bruix et al[6]’s pooled analysis confirmed 
that BCLC C patients had a poorer prognosis than those 
with BCLC B HCC (HR = 1.59; P = 0.02).  
Sorafenib starting dose and dose escalation/
reduction: The two most important studies that 
evaluated sorafenib starting dose and dose escalation/
reduction are SOFIA[32] and GIDEON trial[29].
In the SOFIA trial[32] sorafenib was down-dosed 
in 161 (54%) patients because of AEs (133 patients, 
83%) and a reduction in liver function (28 patients, 
17%). Median OS of the 77 patients receiving a half-
dose of sorafenib for 70% of the treatment period was 
21.6 mo (95%CI: 13.6-29.6) compared with 9.6 mo 
(95%CI: 6.9-12.3) for the remaining 219 patients who 
had a dose reduction for < 70% of the treatment period 
or who maintained the full dosage.
A sub-analysis of the GIDEON study[29] evaluated 
the starting dose of sorafenib with respect to clinical 
outcome and toxicity. Patients starting on 400 mg/
d were slightly older, had baseline characteristics 
indicative of greater disease progression and had a 
higher incidence of AEs than those with a starting dose 
of 800 mg/d (96% vs 88%). Treatment duration (18.0 
wk vs 13.0 wk) and median OS (12.1 mo vs 9.4 mo) 
were longer in patients receiving 800 mg/d.
Etiology: In the subgroup analysis of the SHARP 
study[4], the HR for OS was 0.76 in HBV-positive 
patients (95%CI: 0.38-1.50, P = not significant) and 
0.50 (95%CI: 0.32-0.77) in HCV-positive patients. 
Results were similar for TTP (HR = 1.03 and 0.43 for 
HBV-positive and HCV-positive patients, respectively). 
Similar data were obtained for HBV-positive HCC 
patients in the phase III randomized Asia Pacific trial, 
i.e. the HR for OS was 0.74 (95%CI: 0.51-1.06, 
not significant) with respect to patients with the 
other etiology, for which the HR was 0.57 (95%CI: 
0.29-1.33)[26]. Bruix et al[6]’s pooled analysis of the 
SHARP/Asia Pacific trial results showed that the absence 
of HCV was a potential prognostic factor for poorer 
OS (HR = 0.7, P = 0.02). The same authors revealed 
that HBV-positive patients did not show a significant 
difference in treatment response with respect to their 
HBV-negative counterparts (HR = 0.78; 95%CI: 
0.57-1.06) and OS (HR = 1.128, P = 0.4538). We 
believe that the 2 etiologic groups respond differently to 
sorafenib and that further investigation is warranted in 
specific studies[33]. 
Metformin treatment: Type 2 diabetes is a significant 
risk factor for the development of malignancies, including 
HCC[34]. Casadei Gardini et al[35] published findings 
of reduced sorafenib efficacy in HCC patients treated 
chronically with or without metformin for type II diabetes 
mellitus (PFS 2.6 mo vs 5.0 mo, respectively; and OS 
10.4 mo vs 15.1 mo, respectively). The same authors 
validated these data in a series of more than 250 
cases[36], also highlighting a possible role of sirtuin-3 in 
resistance to sorafenib[37]. Di Costanzo et al[38] recently 
reported an increase in TTP and OS in diabetic with 
respect to non-diabetic HCC patients. However, no 
distinction was made between the different hypoglycemic 
therapies administered.
Immune inflammation indicators
Systemic inflammatory responses have been shown to 
reflect the promotion of angiogenesis, DNA damage and 
tumor invasion through an upregulation of cytokines[39]. 
Previous research revealed that lymphocytes play a 
crucial role in tumor defense by inducing cytotoxic 
cell death and inhibiting tumor cell proliferation and 
migration[40]. Consequently, several inflammation and 
immune-based prognostic scores, such as lymphocyte 
count, neutrophil-lymphocyte ratio (NLR), and systemic 
immune-inflammation index (SII), have been developed 
to predict survival and recurrence in cancers, including 
HCC. Casadei Gardini et al[41] evaluated for the first 
time SII, NLR and platelet-lymphocyte ratio (PLR) in a 
small case series, observing that SII were independent 
prognostic factors for OS. Other studies showed that 
NLR was a significant independent risk factor for shorter 
survival[42,43]. NLR was also found to be an independent 
prognostic factor for both response and survival in Bruix 
et al[6]’s pooled analysis and Lue et al[44]’s retrospective 
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study on Spanish patients.
IMAGING EXAMINATIONS
The response to sorafenib does not correlate with a 
change in lesion dimension, but it is more correlate 
with intralesional vascularization. For this reason, the 
RECIST criteria[45,46] usually used for tumor response 
evaluation is inappropriate to evaluate the response 
to sorafenib in patients with advanced HCC. The 
modified RECIST (mRECIST) appear more indicate for 
evalutation the response. They include vascularization 
and tumor arterial enhancement changes of the target 
lesion on computed tomographic (CT). Several studies 
have demonstrated the superiority of the mRECIST 
criteria with respect to the RECIST criteria in assessing 
the response to treatment with sorafenib[47]. Various 
functional imaging tools were proposed to evaluate the 
antiangiogenic effects, but none of these has entered 
normal clinical practice[48-52]. Finally, a recently study 
showed that texture features on pretreatment contrast 
material-enhanced CT images can help predict OS and 
TTP in these patients[53] .
BIOLOGICAL PARAMETERS 
Serum and plasma proteins
Although plasma biomarkers are the best candidates 
for evaluating sorafenib efficacy, only the SHARP trial 
produced results with borderline significance[4]. Baseline 
angiopoietin-2 (Ang-2) and vascular endothelial 
growth factor-A (VEGF-A) plasma levels independently 
predicted survival in both the entire patient popula-
tion and the placebo cohort. Conversely, none of the 
tested biomarkers significantly predicted response to 
sorafenib[4]. Insulin-like growth factor (IGF)-1 levels 
have been found to decrease in patients with cirrhosis 
of the liver or HCC[54], and high pretreatment levels 
of IGF-1 predict better PFS and OS in advanced HCC 
patients receiving first-line antiangiogenic therapy[55]. 
The role of serum cytokines as biomarkers for the 
prediction of sorafenib responses is interesting, in 
particular Kim et al[56] developed a new prediction model 
for sorafenib response that combines relevant serum 
markers, tumor related factors, and cirrhosis-related 
factors in a scoring system.
VEGF-A: Llovet et al[4] showed that, although baseline 
plasma VEGF-A concentrations did not exhibit a 
predictive value, low plasma VEGF-A was associated 
with improved prognosis (HR = 1.48, 95%CI: 1.08-2.03, 
P = 0.015). However, other authors did not find any 
association between VEGF-A and prognosis in patients 
treated with sorafenib[57]. Tsuchiya et al[58]’s analysis of 
plasma VEGF concentrations during sorafenib treatment 
revealed that a decrease in the protein 8 wk after 
the start of therapy predicted better overall survival 
in advanced HCC patients (30.9 mo vs 14.4 mo; P = 
0.038).
Ang-2: In the presence of VEGF, Ang-2 destabilizes 
blood vessels, promotes vascular sprouting, and is 
associated with an invasive and metastatic cancer 
phenotype[59]. Llovet et al[4] demonstrated that high 
baseline Ang-2 levels were correlated with more 
aggressive disease (HR = 1.58, 95%CI: 1.20-2.07, P = 
0.001). Moreover, levels of the protein increased during 
treatment in the placebo group, suggestive of poor 
outcome related to disease progression in this cohort, 
whereas they remained constant during treatment 
with sorafenib, reflecting the generally more favorable 
outcome of this group. Overall increased Ang-2 
expression levels were associated with poorer outcome 
in both groups, suggesting that this marker could be 
useful in monitoring treatment response. In agreement 
with Llovet’s study, Miyahara et al[57] reported that high 
baseline Ang-2 serum levels were associated with poor 
outcome in advanced HCC patients receiving sorafenib 
(HR = 2.51, 95%CI: 1.01-6.57, P = 0.048). Although 
these results indicate the potential prognostic value 
of Ang-2 in HCC, its role in predicting response to 
sorafenib remains to be verified.
IGF-1: Shao et al[55] found that high-pretreatment 
serum levels of IGF-1 were associated with a better 
DCR and improved PFS and OS in patients undergoing 
antiangiogenic therapy. Although the study did not have 
a control arm, the substantial significant difference 
in DCR between patients with high and low levels of 
IGF-1 (71% vs 39%) denotes the potential usefulness 
of IGF-1 as a predictive biomarker of response to 
antiangiogenic therapy. 
Multiple-factor analyses: By using baseline serum 
basic fibroblast growth factor (bFGF) and hepatocyte 
growth factor (HGF) levels as covariates together 
etiology (B-viral), platelet count, BCLC stage and protein 
induced by vitamin K absence-II, Kim et al[56] reported 
that a total score of < 6 could be a relevant cutoff value 
for selecting patients who are most likely to benefit 
from sorafenib therapy. Moreover, Hayashi et al[60] found 
that serum interleukin (IL)-5, IL-8, CXCL9, PDGF-BB, 
TGF-α, and VEGF-A were elevated in the long survivors 
group among HCC patients who received sorafenib, 
potentially reflecting the activation of stromal signaling 
in the tumor microenvironment.
Genetic markers
Molecular and genomic analyses from tumor and 
non-tumor tissue have proven useful in evaluating 
prognosis and could open up new avenues for tailoring 
treatment[61]. Genetic alterations, such as single 
nucleotide polymorphisms (SNPs) in genes encoding 
for proteins involved in the angiogenic process, 
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have been studied as potential biomarkers for anti-
angiogenic therapy. SNP evaluation would seem to be 
more advantageous than protein or gene expression 
analyses as it can be performed at any time during the 
course of the disease, is not substantially influenced by 
laboratory biases, and is relatively inexpensive. Some 
authors have focused on molecular profiling in formalin-
fixed paraffin-embedded (FFPE) samples, comparing 
the mutation profiles of HCC biopsy samples and the 
response to sorafenib treatment[62]. Gene amplification, 
gene mutations and expression profiling of tumors have 
now become a research priority and are expected to lead 
to personalized treatment for HCC patients[63,64].
SNPs: Specific SNPs in VEGF and VEGFR genes have 
been found to be correlated with PFS and OS in HCC 
patients treated with sorafenib. In multivariate analysis, 
VEGF-A rs2010963 and VEGF-C rs4604006 were 
found to be independent factors influencing outcome 
in terms of PFS (HR = 0.25, 95%CI: 0.19-1.02, P 
= 0.0376 and HR = 0.22, 95%CI: 0.14-0.81, P = 
0.004, respectively) and OS (HR = 0.28, 95%CI: 
0.23-0.96, P = 0.02 and HR = 0.25, 95%CI: 0.17-0.99, 
P = 0.04, respectively)[65]. In the Italian multicenter, 
retrospective ePHAS [endothelial nitric oxide synthase 
(eNOS) polymorphisms in HCC and sorafenib] study, 
eNOS polymorphisms were analyzed in relation to 
PFS and OS. In univariate analysis, training cohort 
patients homozygous for eNOS haplotype (HT1:T-4b at 
eNOS-786/eNOS VNTR) showed a lower median PFS 
(2.6 mo vs 5.8 mo, HR = 5.43, 95%CI: 2.46-11.98, 
P < 0.0001) and OS (3.2 mo vs 14.6 mo, HR = 2.35, 
95%CI: 1.12-4.91, P = 0.024) than those with other 
haplotypes. These results were confirmed in a validation 
set and multivariate analysis further substantiated 
this haplotype as the only independent prognostic 
factor[66]. More recently, evidence emerged that patients 
homozygous for ANGPT2 (Ang2 gene) rs55633437 
GG genotype showed significantly longer PFS (P < 
0.001) and OS (P < 0.001) than those with the other 
genotypes (GT+TT)[67].
In the ALICE-2 study, Faloppi et al[68] investigated 
the role of hypoxia-inducible factor 1-alpha (HIF-1α) 
SNPs, confirming the results of the ALICE-1 study[65]. In 
multivariate analysis, rs12434438 of HIF-1α, rs2010963 
of VEGF-A and rs4604006 of VEGF-C were confirmed as 
independent factors and may help to identify patients 
who are more likely to respond to sorafenib[68]. The 
prospective INNOVATE study is ongoing to validate the 
role of VEGF, eNOS, Ang-2 and HIF-1α SNPs in relation 
to clinical outcome in advanced HCC patients treated 
with sorafenib (NCT02786342)[69].
Gene amplification, gene mutations and RNA 
expression: A relation between VEGF-A gene 
amplification and response to sorafenib was observed 
in a study performed on a mouse model of HCC[70]. 
The authors found that HCC patients with tumor 
VEGF-A amplification showed markedly better survival 
than those with non-amplified tumors, highlighting 
that VEGFA amplification is a potential biomarker of 
response to VEGF-A-blocking drugs in HCC[70]. Arao 
et al[71] observed that FGF3/FGF4 amplification and 
multiple lung metastases were frequently observed in 
responders to sorafenib, although the sample size was 
relatively small.
Sakai et al[62] used targeted DNA and RNA sequencing 
in FFPE specimens from fine-needle biopsy to identify 
candidate biomarkers of response to sorafenib in 46 HCC 
patients. A significant difference was observed in the 
number of oncogene mutations between progressing 
and non-progressing patients (P = 0.045), suggesting 
that tumor mutational burden may be predictive of 
sorafenib effectiveness. Tumor gene expression of NRG1, 
TGFa, and PECAM1 would also seem to be a marker of 
treatment response and PFS.
ΜicroRNAs 
MicroRNAs (miRNAs) affect drug response directly or 
indirectly by regulating the expression of genes involved 
in drug transportation, metabolism, and downstream 
signaling pathways. The deregulation of various miRNAs 
has been reported in in vitro, in vivo and population 
studies[72,73], confirming its correlation with response to 
sorafenib. Some authors have evaluated the predictive 
role of miRNA expression in HCC tissue[74,75], while 
others have studied circulating miRNA levels prior to 
sorafenib treatment[76]. To date, the most interesting 
tissue miRNAs are miR-425-3p[74] and miR-224[75]. 
High levels of miR-425-3p have been associated with 
longer TTP and PFS (HR = 0.4, 95%CI: 0.2-0.7, P = 
0.0008 and HR = 0.5, 95%CI: 0.3-0.9, P = 0.007, 
respectively), and elevated miR-224 expression have 
been correlated with increased PFS and OS (HR = 0.28, 
95%CI: 0.09-0.92, P = 0.029 and HR = 0.0.24, 95%CI: 
0.07-0.79, P = 0.012, respectively). Circulating miRNAs 
have also been studied in the serum of HCC patients 
to predict early response to sorafenib treatment, with 
miR-181a-5p and miR-339-5p associated with partial 
response and disease progression[77], miR-423-5p with 
stable disease or partial response[78] and miR-10b-3p 
with shorter survival[79].
Another potentially interesting circulating miRNA is 
miR-221, which was studied by Fornari et al[76] in both 
animal models and in a patient population. Patients with 
radiologic disease progression after 2-mo treatment had 
higher pretreatment miR-221 levels than responders (P 
= 0.007).
Larger confirmatory studies are needed before 
miRNAs can be considered valid biomarkers for clinical 
practice.
Tissue biomarker expression
 A number of studies have analyzed tissue biomarkers 
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that may be very specific to the disease of interest[80]. 
In a phase II study of sorafenib in advanced HCC, 
Abou-Alfa et al[81] showed that patients whose tumors 
expressed higher baseline phospho-ERK levels had a 
longer TTP. However, other studies reported conflicting 
results[82,83]. With regard to the expression of angiogenic 
markers in tumor tissue, it has been observed that high 
platelet-derived growth factor receptor beta expression 
is correlated with poor OS but not with PFS in HCC 
patients receiving sorafenib. High expression of the 
proto-oncogene c-Met may predict the therapeutic 
effectiveness of sorafenib in HCC patients, but no 
differences in terms of outcome have been seen with 
respect to VEGFR-2 expression[84]. Hagiwara et al[85] 
studied another interesting tissue biomarker, phospho-
c-Jun, reporting a significantly higher expression (P 
< 0.001) in non-responding compared to responding 
patients treated with sorafenib. 
CONCLUSION 
After 10 years of research into sorafenib, there are 
still no validated prognostic or predictive markers of 
response to sorafenib in hepatocellular carcinoma. 
Furthermore, the main results obtained to date come 
from 2 important randomized trials and from different 
subanalyses and pooled analyses rather than from 
normal clinical practice. The fact of there being only one 
drug for the treatment of these patients has certainly 
done nothing to stimulate research into identifying 
and validating predictors of response and prognosis. 
However, given the recent publication of a positive 
phase III trial[86] and the ongoing NCT01658878 
immunotherapy study, the race is now on to see who 
will be the first to identify a prognostic and predictive 
factor for sorafenib and/or new drugs in this setting. In 
conclusion, the use of metabolomic profiling and whole 
genome analysis to examine the association between 
patient outcome and response to sorafenib could 
become alternative approaches to the search for new 
biomarkers in HCC.
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